PR: Heidelberg Pharma to Participate in Leading Scientific and Financial Conferences in November 2024
Ladenburg, Germany, 24 October 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), announces it will present its ADC candidates and ADC technology platforms at leading scientific and financial conferences throughout November.
The Company’s most advanced Amanitin-based ADC product candidate, HDP-101, is currently in a Phase I/IIa trial for the treatment of relapsed or refractory multiple myeloma. In late September, Heidelberg Pharma presented clinical data from the fifth patient cohort, demonstrating a case of complete remission in a patient who had been treated multiple times. This patient showed a partial response after the second treatment cycle, with a complete remission observed after 11 cycles. In addition, several patients exhibited promising biological activity and objective improvements, underscoring the potential of HDP-101 as a treatment option for patients with this disease.
HDP-201, Heidelberg Pharma’s first Exatecan-based ADC candidate, is a topoisomerase I inhibitor that has proven success in cancer therapy and is already used in two approved ADCs. Its distinct mode of action from Amanitin broadens the Company’s portfolio of active ingredients. HDP-201 targets guanylyl cyclase-C (GCC), a receptor expressed on the surface of intestinal cells and cancer cells in various gastrointestinal tumors. Preclinical data suggest that the tolerability and efficacy of HDP-201 is at least on a par with existing, approved Exatecan-based ADCs. Following extensive preclinical testing, the final development candidate for HDP-201 was determined in recent weeks, with colorectal cancer identified as the target indication for its clinical development.
|
Date & location: |
4 – 7 November 2024 San Diego, California, USA |
|
Workshop: |
2nd Biomarker & Patient Selection Day |
|
Date: |
4 November, 10:30 am PST |
|
Title of presentation: |
Leveraging 17p Deletion as a Biomarker & Patient Selection Tool for Amanitin Payload ADCs |
|
Presenter: |
Anikó Pálfi, Director Biochemistry & Cell Biology |
|
|
|
|
Stream: |
Discovery Chemistry |
|
Date: |
6 November, 2:00 pm PST |
|
Title of presentation: |
HDP-201, a Multimeric Linker-Exatecan-based ADC as Novel Therapeutic Modality for Treatment of Solid Tumors |
|
Presenter: |
Professor Andreas Pahl, CEO |
|
|
|
|
Plenary: |
BCMA Breakdown: Exploring Case Studies of ADC Development for Targets Without an Approved Therapy |
|
Date: |
6 November, 4:00 pm PST |
|
Title of presentation: |
ATACs: A New Payload Provides New Options for Cancer Therapy |
|
Presenter: |
Dr. Torsten Hechler, Senior Vice President ADC Research |
|
Date & location: |
25 – 27 November 2024, Frankfurt, Germany |
|
Panel: |
Company Presentations (Room Zurich) |
|
Date: |
26 November, 11:15 am MEZ |
|
Title of presentation: |
Leader in Next Generation ADC Payloads |
|
Presenter: |
Walter Miller, Chief Financial Officer |
Walter Miller will be available for one-on-one meetings, which can be arranged via the online conference system.